The Role of Interventional Radiologists in the Treatment of Congenital Lymphatic Malformations

Abstract

Lymphatic malformations are low-flow vascular malformations that are typically apparent in the pediatric population and can cause significant functional limitations and effects on quality of life. While surgical resection has historically been the mainstay of therapy, percutaneous sclerotherapy has garnered increasing popularity due to its efficacy and low complication rates. The role of interventional radiology in the multidisciplinary management of these often complex malformations requires thorough understanding of the disease process. This article will review the pathophysiology, clinical presentation, imaging workup, and management options of lymphatic malformations. Special attention will be devoted to available sclerosants, the mammalian target of rapamycin inhibitor sirolimus, and complex lymphatic anomalies.

Keywords

lymphatic malformation - sclerotherapy - sirolimus

Notes

No funding was received for this study. The data have not been submitted for presentation at any meeting.

• References

• 1 Kennedy TL, Whitaker M, Pellitteri P, Wood WE. Cystic hygroma/lymphangioma: a rational approach to management. Laryngoscope 2001; 111 (11, Pt 1): 1929-1937
• 2 Wassef M, Blei F, Adams D. , et al; ISSVA Board and Scientific Committee. Vascular anomalies classification: recommendations from the international society for the study of vascular anomalies. Pediatrics 2015; 136 (01) e203-e214
• 3 Hawkins CM, Chewning RH. Diagnosis and management of extracranial vascular malformations in children: arteriovenous malformations, venous malformations, and lymphatic malformations. Semin Roentgenol 2019; 54 (04) 337-348
• 4 Perkins JA, Manning SC, Tempero RM. , et al. Lymphatic malformations: review of current treatment. Otolaryngol Head Neck Surg 2010; 142 (06) 795-803 , 803.e1
• 5 Elluru RG, Balakrishnan K, Padua HM. Lymphatic malformations: diagnosis and management. Semin Pediatr Surg 2014; 23 (04) 178-185
• 6 Cahill AM, Nijs EL. Pediatric vascular malformations: pathophysiology, diagnosis, and the role of interventional radiology. Cardiovasc Intervent Radiol 2011; 34 (04) 691-704
• 7 Defnet AM, Bagrodia N, Hernandez SL, Gwilliam N, Kandel JJ. Pediatric lymphatic malformations: evolving understanding and therapeutic options. Pediatr Surg Int 2016; 32 (05) 425-433
• 8 Puig S, Casati B, Staudenherz A, Paya K. Vascular low-flow malformations in children: current concepts for classification, diagnosis and therapy. Eur J Radiol 2005; 53 (01) 35-45
• 9 Bertino F, Braithwaite KA, Hawkins CM. , et al. congenital limb overgrowth syndromes associated with vascular anomalies. Radiographics 2019; 39 (02) 491-515
• 10 Bertino F, Chaudry G. overgrowth syndromes associated with vascular anomalies. Semin Roentgenol 2019; 54 (04) 349-358
• 11 Keppler-Noreuil KM, Parker VE, Darling TN, Martinez-Agosto JA. Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies. Am J Med Genet C Semin Med Genet 2016; 172 (04) 402-421
• 12 Michelini S, Paolacci S, Manara E. , et al. Genetic tests in lymphatic vascular malformations and lymphedema. J Med Genet 2018; 55 (04) 222-232
• 13 di Blasio L, Puliafito A, Gagliardi PA. , et al. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations. Cell Death Dis 2018; 9 (02) 45
• 14 Burrows PE. Endovascular treatment of slow-flow vascular malformations. Tech Vasc Interv Radiol 2013; 16 (01) 12-21
• 15 Dubois J, Alison M. Vascular anomalies: what a radiologist needs to know. Pediatr Radiol 2010; 40 (06) 895-905
• 16 Trenor III CC, Chaudry G. Complex lymphatic anomalies. Semin Pediatr Surg 2014; 23 (04) 186-190
• 17 Paltiel HJ, Burrows PE, Kozakewich HP, Zurakowski D, Mulliken JB. Soft-tissue vascular anomalies: utility of US for diagnosis. Radiology 2000; 214 (03) 747-754
• 18 Tempero RM, Hannibal M, Finn LS, Manning SC, Cunningham ML, Perkins JA. Lymphocytopenia in children with lymphatic malformation. Arch Otolaryngol Head Neck Surg 2006; 132 (01) 93-97
• 19 Goyal P, Alomari AI, Kozakewich HP. , et al. Imaging features of kaposiform lymphangiomatosis. Pediatr Radiol 2016; 46 (09) 1282-1290
• 20 Le Cras TD, Mobberley-Schuman PS, Broering M, Fei L, Trenor III CC, Adams DM. Angiopoietins as serum biomarkers for lymphatic anomalies. Angiogenesis 2017; 20 (01) 163-173
• 21 White CL, Olivieri B, Restrepo R, McKeon B, Karakas SP, Lee EY. Low-flow vascular malformation pitfalls: from clinical examination to practical imaging evaluation--Part 1, Lymphatic malformation mimickers. AJR Am J Roentgenol 2016; 206 (05) 940-951
• 22 Sadick M, Müller-Wille R, Wildgruber M, Wohlgemuth WA. Vascular anomalies (Part I): classification and diagnostics of vascular anomalies. RoFo Fortschr Geb Rontgenstr Nuklearmed 2018; 190 (09) 825-835
• 23 Francavilla ML, White CL, Oliveri B, Lee EY, Restrepo R. Intraabdominal lymphatic malformations: pearls and pitfalls of diagnosis and differential diagnoses in pediatric patients. AJR Am J Roentgenol 2017; 208 (03) 637-649
• 24 Merrow AC, Gupta A, Patel MN, Adams DM. 2014 Revised classification of vascular lesions from the international society for the study of vascular anomalies: radiologic-pathologic update. Radiographics 2016; 36 (05) 1494-1516
• 25 Balakrishnan K, Bauman N, Chun RH. , et al. Standardized outcome and reporting measures in pediatric head and neck lymphatic malformations. Otolaryngol Head Neck Surg 2015; 152 (05) 948-953
• 26 Adams MT, Saltzman B, Perkins JA. Head and neck lymphatic malformation treatment: a systematic review. Otolaryngol Head Neck Surg 2012; 147 (04) 627-639
• 27 Ono Y, Osuga K, Takura T. , et al. Cost-effectiveness analysis of percutaneous sclerotherapy for venous malformations. J Vasc Interv Radiol 2016; 27 (06) 831-837
• 28 Mathur NN, Rana I, Bothra R, Dhawan R, Kathuria G, Pradhan T. Bleomycin sclerotherapy in congenital lymphatic and vascular malformations of head and neck. Int J Pediatr Otorhinolaryngol 2005; 69 (01) 75-80
• 29 Acord M, Srinivasan AS, Cahill AM. percutaneous treatment of lymphatic malformations. Tech Vasc Interv Radiol 2016; 19 (04) 305-311
• 30 De Maria L, De Sanctis P, Balakrishnan K, Tollefson M, Brinjikji W. Sclerotherapy for lymphatic malformations of head and neck: systematic review and meta-analysis. J Vasc Surg Venous Lymphat Disord 2020; 8 (01) 154-164
• 31 Burrows PE, Mitri RK, Alomari A. , et al. Percutaneous sclerotherapy of lymphatic malformations with doxycycline. Lymphat Res Biol 2008; 6 (3-4): 209-216
• 32 Molitch HI, Unger EC, Witte CL, vanSonnenberg E. Percutaneous sclerotherapy of lymphangiomas. Radiology 1995; 194 (02) 343-347
• 33 Farnoosh S, Don D, Koempel J, Panossian A, Anselmo D, Stanley P. Efficacy of doxycycline and sodium tetradecyl sulfate sclerotherapy in pediatric head and neck lymphatic malformations. Int J Pediatr Otorhinolaryngol 2015; 79 (06) 883-887
• 34 Thomas DM, Wieck MM, Grant CN. , et al. Doxycycline sclerotherapy is superior in the treatment of pediatric lymphatic malformations. J Vasc Interv Radiol 2016; 27 (12) 1846-1856
• 35 Shergill A, John P, Amaral JG. Doxycycline sclerotherapy in children with lymphatic malformations: outcomes, complications and clinical efficacy. Pediatr Radiol 2012; 42 (09) 1080-1088
• 36 Chaudry G, Burrows PE, Padua HM, Dillon BJ, Fishman SJ, Alomari AI. Sclerotherapy of abdominal lymphatic malformations with doxycycline. J Vasc Interv Radiol 2011; 22 (10) 1431-1435
• 37 Tu JH, Do HM, Patel V, Yeom KW, Teng JMC. Sclerotherapy for lymphatic malformations of the head and neck in the pediatric population. J Neurointerv Surg 2017; 9 (10) 1023-1026
• 38 Bagrodia N, Defnet AM, Kandel JJ. Management of lymphatic malformations in children. Curr Opin Pediatr 2015; 27 (03) 356-363
• 39 Chaudry G, Guevara CJ, Rialon KL. , et al. Safety and efficacy of bleomycin sclerotherapy for microcystic lymphatic malformation. Cardiovasc Intervent Radiol 2014; 37 (06) 1476-1481
• 40 Azene E, Mitchell S, Radvany M, Agrawal N, Eisele D, Weiss C. Foamed bleomycin sclerosis of airway venous malformations: The role of interspecialty collaboration. Laryngoscope 2016; 126 (12) 2726-2732
• 41 Ul Haq F, Mitchell SE, Tekes A, Weiss CR. Bleomycin foam treatment of venous malformations: a promising agent for effective treatment with minimal swelling. J Vasc Interv Radiol 2015; 26 (10) 1484-1493
• 42 Chen AW, Wang T, Huang YY, Liu SH. Multistage sclerotherapy for extensive lymphatic malformations with airway involvement in infant: a protocol to prevent tracheotomy. J Oral Maxillofac Surg 2017; 75 (09) 1882-1890
• 43 Wratney AT, Benjamin Jr DK, Slonim AD, He J, Hamel DS, Cheifetz IM. The endotracheal tube air leak test does not predict extubation outcome in critically ill pediatric patients. Pediatr Crit Care Med 2008; 9 (05) 490-496
• 44 Hanif AM, Saunders JA, Hawkins CM, Wojno TH, Kim HJ. Use of percutaneous bleomycin sclerotherapy for orbital lymphatic malformations. Orbit 2019; 38 (01) 30-36
• 45 MacIntosh PW, Yoon MK, Fay A. Complications of intralesional bleomycin in the treatment of orbital lymphatic malformations. Semin Ophthalmol 2014; 29 (5-6): 450-455
• 46 Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001; 120 (02) 617-624
• 47 Liu T, De Los Santos FG, Phan SH. The bleomycin model of pulmonary fibrosis. Methods Mol Biol 2017; 1627: 27-42
• 48 Roden AC, Camus P. Iatrogenic pulmonary lesions. Semin Diagn Pathol 2018; 35 (04) 260-271
• 49 O'Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003; 14 (01) 91-96
• 50 Muir T, Kirsten M, Fourie P, Dippenaar N, Ionescu GO. Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int 2004; 19 (12) 766-773
• 51 Méndez-Echevarría A, Fernandez-Prieto A, de la Serna O. , et al. acute lung toxicity after intralesional bleomycin sclerotherapy. Pediatrics 2018; 141 (01) e20161787
• 52 Atwa K, Abuhasna S, Shihab Z, Hashaykeh N, Hasan R. Acute pulmonary toxicity following intralesional administration of bleomycin for a lymphovenous malformation. Pediatr Pulmonol 2010; 45 (02) 192-196
• 53 Lam MS. The need for routine bleomycin test dosing in the 21st century. Ann Pharmacother 2005; 39 (11) 1897-1902
• 54 Poldervaart MT, Breugem CC, Speleman L, Pasmans S. Treatment of lymphatic malformations with OK-432 (Picibanil): review of the literature. J Craniofac Surg 2009; 20 (04) 1159-1162
• 55 Ghaffarpour N, Petrini B, Svensson LA, Boman K, Wester T, Claesson G. Patients with lymphatic malformations who receive the immunostimulant OK-432 experience excellent long-term outcomes. Acta Paediatr 2015; 104 (11) 1169-1173
• 56 Motz KM, Nickley KB, Bedwell JR. , et al. OK432 versus doxycycline for treatment of macrocystic lymphatic malformations. Ann Otol Rhinol Laryngol 2014; 123 (02) 81-88
• 57 Horbach SE, Lokhorst MM, Saeed P, de Goüyon Matignon de Pontouraude CM, Rothová A, van der Horst CM. Sclerotherapy for low-flow vascular malformations of the head and neck: a systematic review of sclerosing agents. J Plast Reconstr Aesthet Surg 2016; 69 (03) 295-304
• 58 Kim SW, Kavanagh K, Orbach DB, Alomari AI, Mulliken JB, Rahbar R. Long-term outcome of radiofrequency ablation for intraoral microcystic lymphatic malformation. Arch Otolaryngol Head Neck Surg 2011; 137 (12) 1247-1250
• 59 Lisan Q, Villepelet A, Parodi M. , et al. Value of radiofrequency ablation in the management of retropharyngeal lymphatic malformation. Int J Pediatr Otorhinolaryngol 2016; 83: 37-40
• 60 Ramaswamy RS, Tiwari T, Darcy MD. , et al. Cryoablation of low-flow vascular malformations. Diagn Interv Radiol 2019; 25 (03) 225-230
• 61 Thompson SM, Callstrom MR, McKusick MA, Woodrum DA. Initial results of image-guided percutaneous ablation as second-line treatment for symptomatic vascular anomalies. Cardiovasc Intervent Radiol 2015; 38 (05) 1171-1178
• 62 Savas JA, Ledon J, Franca K, Chacon A, Zaiac M, Nouri K. Carbon dioxide laser for the treatment of microcystic lymphatic malformations (lymphangioma circumscriptum): a systematic review. Dermatol Surg 2013; 39 (08) 1147-1157
• 63 França K, Chacon A, Ledon J, Savas J, Izakovic J, Nouri K. Lasers for cutaneous congenital vascular lesions: a comprehensive overview and update. Lasers Med Sci 2013; 28 (04) 1197-1204
• 64 Mulliken JB, Fishman SJ, Burrows PE. Vascular anomalies. Curr Probl Surg 2000; 37 (08) 517-584
• 65 Alqahtani A, Nguyen LT, Flageole H, Shaw K, Laberge JM. 25 years' experience with lymphangiomas in children. J Pediatr Surg 1999; 34 (07) 1164-1168
• 66 Wiegand S, Wichmann G, Dietz A. Treatment of lymphatic malformations with the mTOR inhibitor sirolimus: a systematic review. Lymphat Res Biol 2018; 16 (04) 330-339
• 67 Hammill AM, Wentzel M, Gupta A. , et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011; 57 (06) 1018-1024
• 68 Strychowsky JE, Rahbar R, O'Hare MJ, Irace AL, Padua H, Trenor III CC. Sirolimus as treatment for 19 patients with refractory cervicofacial lymphatic malformation. Laryngoscope 2018; 128 (01) 269-276
• 69 Ricci KW, Hammill AM, Mobberley-Schuman P. , et al. Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease. Pediatr Blood Cancer 2019; 66 (05) e27614
• 70 McCormack FX, Inoue Y, Moss J. , et al; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364 (17) 1595-1606
• 71 Arriola Apelo SI, Lamming DW. Rapamycin: an InhibiTOR of aging emerges from the soil of Easter Island. J Gerontol A Biol Sci Med Sci 2016; 71 (07) 841-849
• 72 Croteau SE, Kozakewich HP, Perez-Atayde AR. , et al. Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly. J Pediatr 2014; 164 (02) 383-388
• 73 Ozeki M, Fujino A, Matsuoka K, Nosaka S, Kuroda T, Fukao T. Clinical features and prognosis of generalized lymphatic anomaly, Kaposiform lymphangiomatosis, and Gorham-Stout disease. Pediatr Blood Cancer 2016; 63 (05) 832-838
• 74 Steiner JE, Drolet BA. Classification of vascular anomalies: an update. Semin Intervent Radiol 2017; 34 (03) 225-232
• 75 Grada AA, Phillips TJ. Lymphedema: pathophysiology and clinical manifestations. J Am Acad Dermatol 2017; 77 (06) 1009-1020
• 76 Lala S, Mulliken JB, Alomari AI, Fishman SJ, Kozakewich HP, Chaudry G. Gorham-Stout disease and generalized lymphatic anomaly--clinical, radiologic, and histologic differentiation. Skeletal Radiol 2013; 42 (07) 917-924
• 77 Kato H, Ozeki M, Fukao T, Matsuo M. MR imaging findings of vertebral involvement in Gorham-Stout disease, generalized lymphatic anomaly, and kaposiform lymphangiomatosis. Jpn J Radiol 2017; 35 (10) 606-612
• 78 Chavhan GB, Amaral JG, Temple M, Itkin M. MR lymphangiography in children: technique and potential applications. Radiographics 2017; 37 (06) 1775-1790